Стандартные и инновационные методы терапии системной красной волчанки


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В представленном обзоре литературы описаны сохраняющие свое значение стандартные методы терапии системной красной волчанки, включая глюкокортикостероиды, цитостатческие и аминохинолиновые препараты. Обсуждаются перспективы инновационных методов лечения: анти В-клеточная терапия; применение ингибиторов интерферона, JAK-STAT и провоспалительных цитокинов.

Полный текст

Доступ закрыт

Об авторах

Е. А Асеева

Научно-исследовательский институт ревматологии им. В.А. Насоновой

Email: eaasseeva@mail.ru

С. К Соловьев

КДЦБ МЕДСИ

Н. Ю Никишина

КДЦБ МЕДСИ

Е. Л Насонов

Научно-исследовательский институт ревматологии им. В.А. Насоновой

А. М Лила

Научно-исследовательский институт ревматологии им. В.А. Насоновой

Список литературы

  1. Michelson H. The problem of lupus erythematosus. Calif Med. 1949;70(1):5-9.Hench PS., Kendall E.C., Slocumb CH., Polley H.F. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions: A study in clinical physiology, Arch Int Med. 1950;85(4):545-666. doi: 10.1001/archinte.1950.00230100002001.
  2. Насонов Е.Л., Российские клинические рекомендации. Ревматология М., 2017. 464 с
  3. Wallace D.J. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol 2015;11:616-20. doi: 10.1038/nrrheum.2015.86
  4. Mosca M., Tani C., Carli L., et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol. 2011;29(5 Suppl. 68):S126-29.
  5. Apostolopoulos D., Morand E.F. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatol. (Oxford). 2017;56(Suppl. 1):i114-22. doi: 10.1093/rheumatology/kew406.
  6. Fanouriakis A., Kostopoulou M., Alunno A., et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. Doi: 10.1136/ annrheumdis-2019-215089.
  7. Gladman D.D., Urowitz M.B., Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955-59.
  8. Zonana-Nacach A., Barr S.G., Magder L.S., et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthr Rheum. 2000;43:1801-808. doi: 10.1002/1529-0131(200008)43:8<1801:: AID-ANR16>3.0.C0;2-0.
  9. Dixon W.G., Abrahamowicz M., Beauchamp M.-E., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71:1128-33. Doi: 10.1136/ annrheumdis-2011-200702.
  10. Bruce I.N. 'Not only.. but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatol. 2005;44:1492-502. Doi: 10.1093/ rheumatology/kei142.
  11. Bhangle S.D., Kramer N., Rosenstein E.D. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33:1923-32. doi: 10.1007/s00296-013-2750-z.
  12. Carter E.E., Barr S.G., Clarke A.E. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. doi: 10.1038/nrrheum.2016.137.
  13. Barber M.R.W, Clarke A.E. Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29(5):480-85. doi: 10.1097/ B0R.0000000000000416.
  14. van Vollenhoven R.F., Mosca M., Bertsias G., et al. Treat-to-target in systemic lupus rythematosus: recommendations from an international Task Force. Ann Rheum Dis. 2014;73:958-67. Doi:10.1136/ annrheumdis-2013-205139.
  15. Соловьев С.К., Асеева Е.А., Зоткин Е.Г. и др. Проблемы низкой активности и ремиссии при системной красной волчанке Научно-практическая ревматология. 2019;57(2):218-21. [Soloviev S.K., Aseeva E.A., Zotkin E.G., et al. Problems of low activity and remission in systemic lupus erythematosus Nauchno-prakticheskaya revmatologiya. 2019;57(2):218-21. (In Russ.)].
  16. Соловьев С.К., Асеева Е.А., Насонов Е.Л. и др. Возможности и перспективы отмены глюкокортикои-дов при системной красной волчанке. Современная ревматология. 2020;14(1):6-11. [Soloviev S.K., Aseeva E.A., Nasonov E.L., et al. Possibilities and prospects of glucocorticoid withdrawal in systemic lupus erythematosus. Sovremennaya revmatologiya. 2020;14(1):6-11. (In Russ.)].
  17. Durcan L., O'Dwyer T., Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-43. doi: 10.1016/S0140-6736(19)30237-5.
  18. Drner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344-58. doi: 10.1016/S0140-6736(19)30546-X.
  19. Соловьев С.К., Асеева Е.А., Попкова Т.В. и др. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. [Soloviev S.K., Aseeva E.A., Popkova T.V. et al. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Nauchno-prakticheskaya revmatologiya. 2020;58(1):5-14. (In Russ.)].
  20. Laurie S., Reimold A.M. Research and therapeutics -traditional and emerging therapies in systemic lupus erythematosus. Rheumatol. (Oxford). 2017;56(Suppl. 1):i100-13.
  21. Fassbinder T., Saunders U., Mickholz E., et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthr Res Ther. 2015;17:92. doi: 10.1186/s13075-015-0603-8.
  22. Mok C.C. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12(4):221-34. Doi: 10.1038/ nrrheum.2015.174.
  23. Rainsford K.D., Parke A.L., Clifford-Rashotte M., Kean W.F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacol. 2015;23:231 69. doi: 10.1007/s10787-015-0239-y
  24. James J.A., Kim-Howard X.R., Bruner B.F., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16:401-9. doi: 10.1177/0961203307078579.
  25. Abarientos C., Sperber K., Shapiro D.L., et al. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Safety. 2011;10:705-14. Doi:10.15 17/14740338.2011.566555.
  26. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5(Suppl. 1):S4-10.
  27. Fortin PR., Abrahamowicz M., Ferland D., et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2008;59:1796-804.
  28. Pego-Reigosa J.M., Cobo-Ibanez T., Calvo-Alen J., et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthr Care Res. 2013;65:1775-85. doi: 10.1002/acr.22035.
  29. Bao H., Liu Z.H., Xie H.L., et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-10. Doi:10.1681/ ASN.2007121272.
  30. Liu Z., Zhang H., Liu Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Int Med. 2015;162:18-26. Doi:10.7326/ M14-1030.
  31. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Монография. Под ред. Е.Л. Насонова. М., 2011. 344 с.: ил. [Anti-B-cell therapy in rheumatology: focus on rituximab. Monograph. Ed. by E.L. Nasonov. M., 2011. 344 p. (In Russ.)].
  32. Duxbury B., Combescure C., Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489-503. doi: 10.1177/0961203313509295.
  33. Цанян М.Э., Соловьев С.К., Торгашина А.В. и др. Эффективность терапии ритуксимабом у больных рефрактерной к стандартной терапии системной красной волчанкой при длительном динамическом наблюдении. Научно-практическая ревматология. 2014;52(2):159-68. [Tsanyan M.E., Soloviev S.K., Torgashina A.V. et al. The effectiveness of rituximab therapy in patients with refractory to standard therapy with systemic lupus erythematosus with long-term follow-up. Nauchno-prakticheskaya revmatologiya. 2014;52(2):159-68. (In Russ.)].
  34. Reddy V., Dahal L.N., Cragg M.S., Leandro M. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016;21:1330-38. doi: 10.1016/j.drudis.2016.06.009.
  35. Mysler E.F., Spindler A.J., Guzman R., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthr Rheum. 2013;65:2368-79. doi: 10.1002/art.38037.
  36. Dorner T., Shock A., Goldenberg D.M., Lipsky P.E. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmun Rev. 2015;14:1079-86. Doi: 10.1016/j. autrev.2015.07.013.
  37. Vilas-Boas A., Morais S.A., Isenberg D.A. Belimumab in systemic lupus erythematosus. RMD Open. 2015;1:e000011. Doi: 10.1136/ rmdopen-2014-000011.
  38. Асеева Е.А., Соловьев С.К., Меснянкина А.А., Насонов Е.Л. и др. Результаты наблюдательного проспективного исследования эффективности и безопасности белимумаба (Бенлисты®) при системной красной волчанке в реальной клинической практике. Научно-практическая ревматология. 2016;54(1):31-7.
  39. Меснянкина А.А., Соловьев С.К., Асеева Е.А., Насонов Е.Л. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9. [Mesnyankina A.A., Soloviev S.K., Aseeva E.A., Nasonov E.L. Efficiency of genetically engineered biological therapy and features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2018;56(3):302-9. (In Russ.)].
  40. Vincent F.B., Morand E.F., Schneider P., Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nature reviews. Rheumatol. 2014;10:365-73. doi: 10.1038/ nrrheum.2014.33.
  41. Duxbury B., Combescure C., Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489-503. doi: 10.1177/0961203313509295.
  42. Samotij D., Reich A. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. BioMed Res Int. 2019;Article ID 8142368:17. doi: 10.1155/2019/8142368.
  43. Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskel. Dis. 2019;11:1-9. doi: 10.1177/1759720X19874309.
  44. McCarthy E.M, Sutton E., Nesbit S., et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatol (Oxford). 2018;57(3):470-79. doi: 10.1093/rheumatology/kex395.
  45. Chavarot N.,Verhelst D., Pardon A., et al. Rituximab alone as induction therapy for membranous lupus nephritis A multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. Doi:10.1097/ MD.0000000000007429.
  46. Насонов Е.Л., Соловьев С.К. Перспективы фармакотерапии системной красной волчанки. Научно-практическая ревматология. 2014;52(3):311-21. [Nasonov E.L., Soloviev S.K. Prospects for the pharmacotherapy of systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2014;52(3):311-21. (In Russ.)].
  47. Condon M.B., Ashby D., Pepper R.J., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280-86. Doi: 10.1136/ annrheumdis-2012-202844.
  48. Gracia-Tello B., Ezeonyeji A., Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci. Med. 2017;4(1):e000182. doi: 10.1136/lupus-2016000182.
  49. Sramek M., Neradil J., Veselska R. Much more than you expected: the non-DHFR-mediated effects of methotrexate. Biochim Biophys Acta Gen Subj. 2017;1861:499-503. Doi: 10.1016/j. bbagen.2016.12.014.
  50. Chan E.S.L., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthr Res. 2002;4:266-73. doi: 10.1186/ar419.
  51. Sakthiswary R., Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23(3):225-35. doi: 10.1177/0961203313519159.
  52. Насонов Е.Л. Метотрексат при ревматоидном артрите - 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33. [Nasonov E.L. Methotrexate for rheumatoid arthritis - 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya. 2015;53(4):421-33. (In Russ.)].
  53. Gansauge S., Breitbart A., Rinaldi N., Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56(6):382-85. doi: 10.1136/ard.56.6.382.
  54. Andersson J., Nagy S., Groth C.G, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunol. 1992;75(1):136-42.
  55. Mok C.C. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):429-38. Doi: 10.1016/j. berh.2017.09.010.
  56. Zhou T, Lin S., Yang S., Lin W. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 2019;13:857-69. doi: 10.2147/DDDT.S189156.
  57. Chen W., Tang X., Liu Q., et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44. Doi: 10.1053/j. ajkd.2010.08.036.
  58. Wang S., Li X., Qu L., et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012;21(9):1025 35. doi: 10.1177/0961203312448105
  59. Zhang H., Hu W., Xie H., et al. Randomized controlled trial of tacrolimus versus intravenous cyclophosphamide in the induction trerapy of class V plus IV lupus nephritis. J Nephrol Dialy Transplant. 2006;15(6):508-14.
  60. Mok C.C., Ying K.Y., Yim C.W., et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456.
  61. Li X., Ren H., Zhang Q., et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4):1467-72. doi: 10.1093/ndt/gfr484.
  62. Liu Z., Zhang H., Liu Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. doi: 10.7326/M14-1030.
  63. Sakai R., Kurasawa T., Nishi E., et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus. 2018;27(2):273-82. doi: 10.1177/0961203317719148.
  64. Jesus D., Rodrigues M., da Silva J.A.P, Ins L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27(8):1358-62. doi: 10.1177/0961203318758508.
  65. Wiederrecht G., Lam E., Hung S., et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci. 1993;696:9-19. doi: 10.1111/j.1749-6632.1993. tb17137.x.
  66. Mok C.C. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:429e438. doi: 10.1016/j. berh.2017.09.010.
  67. B rsan T., Dambrin C., Freitag D.G., et al. The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl Int. 2005;17:767e71. doi: 10.1007/s00147-004-0799-z.
  68. Dooley M.A., Pendergraft III W., Ginzler E.M., et al. Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract] Arthr Rheumatol. 2016;68(Suppl. 10).
  69. Navarra S.V., Guzman R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31. doi: 10.1016/S0140-6736(10)61354-2.
  70. Furie R., Petri M., Zamani O., et al. A phase II, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rheum. 2011;63:3918-30. doi: 10.1002/art.30613.
  71. Strand V., Levy R.A., Cervera R., et al. BLISS-52 and -76 study groups. Improvements in health-related quality of life with belimumab, a B lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014; 73:838-44.
  72. Zhang F, Bae S.C., Bass D., et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355-63. Doi: 10.1136/ annrheumdis-2017-211631
  73. Guerreiro Castro S., Isenberg D.A. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther AdvMusculoskelet Dis. 2017;9(3):75 85. doi: 10.1177/1759720X17690474
  74. Stohl W., Schwarting A., Okada M., et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, doubleblind, placebo-controlled study. Arthr Rheumatol. 2017;69:1016-27. doi: 10.1002/art.40049.
  75. Doria A, Bass D., Schwarting A., et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018;27:1489-98. doi: 10.1177/0961203318777634.
  76. Lavie F., Miceli-Richard C., Ittah M., et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment:insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66(5):700-3. doi: 10.1136/ard.2006.060772.
  77. Carter L.M., Isenberg D.A., Ehrenstein M.R. Elevated serum BAFF levels are associated with rising antidouble-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthr Rheum. 2013;65(10):2672-9. doi: 10.1002/art.38074.
  78. Ehrenstein M.R., Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72. doi: 10.1038/nrrheum.2016.18.
  79. Petri M., Stohl W., Chatham W., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthr Rheum. 2008;58:2453-59. doi: 10.1002/art.23678.
  80. Wei Yu Lin, Seshasayee D., lee W.P, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthr Rheum. 2015;67(1):215-24. doi: 10.1002/art.38907.
  81. Kraaij T, Huizinga T.W., Rabelink T.J., et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatol. 2014;53:2122-24. doi: 10.1093/rheumatology/keu369.
  82. De Vita S., QuartuccioL.,Salvin S., etal. Sequential therapy with belimumab followed by rituximab in Sjo gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF:evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32(4):490-94.
  83. Меснянкина А.А., Соловьев С.К., Александрова Е.Н. и др. Двойная терапия генно-инженерными биологическими препаратами у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2016;54(3):281-88. [Mesnyankina A.A., Soloviev S.K., Alexandrova E.N. et al. Dual therapy with genetically engineered biological drugs in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2016;54(3):281-88. (In Russ.)].
  84. Jones A., Muller P., Dore C.J., et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9( 12):e032569. Doi: 10.1136/ bmjopen-2019-032569.
  85. Larosa M., Zen M., Gatto M., et al. IL-12 and IL-23/ Th17 axis in systemic lupus erythematosus. Exp Biol Med. (Maywood). 2019;244(1):42-51. doi: 10.1177/1535370218824547.
  86. Dai H., He F., Tsokos G.C., Kyttaris V.C. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus. J Immunol. 2017;199(3):903-10. doi: 10.4049/jimmunol.1700418.
  87. van Vollenhoven R.F., Hahn B.H., Tsokos G.C., Lipsky P., et al. Maintenance of efficacy and safety of ustekinumab through 1 year in a randomized phase II trial of patients with active systemic lupus erythematosus. Arthr Rheumatol. 2019 Nov 25. doi: 10.1002/art.41179.
  88. Насонов Е.Л, Соловьев С.К. Перспективы фармакотерапии системной красной волчанки. Научнопрактическая ревматология. 2014;52(3):311-21. https://doi.org/10.14412/1995-4484-2014-311-321
  89. Felten R., Scher F, Sagez F, et al. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des. Devel Ther. 2019; 13:1535 43. doi: 10.2147/DDDT.S170969
  90. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. Doi:https://doi.org/10.14412/1995-4484-2019-8-16
  91. Konig N., Fiehn C., Wolf C., et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72. Doi: 10.1136/ annrheumdis-2016-209841.
  92. Rodero M.P, Fremond M.-L., Rice G.I., et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis 2016;75(12):e75-5. Doi: 10.1136/ annrheumdis-2016-210504.
  93. Hildebrand A.M., Huang S.H., Clark W.F Plasma exchange for kidney disease: What is the best evidence? Adv Chronic Kidney Dis. 2014;21:217-27. doi: 10.1053/j.ackd.2014.01.008.
  94. Pagnoux C., Korach J.M., Guillevin L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus. 2005;14:871-77. doi: 10.1191/0961203305lu2174rr.
  95. Walters G. Role of therapeutic plasmapheresis in ANCA -associated vasculitis. Pediatr Nephrol. 2016;31:217-
  96. doi: 10.1007/s00467-014-3038-6.
  97. Frausova D., Hruskova Z., Lanska V., et al. Longterm outcome of patients with ANCA-associated vasculitis treated with plasma exchange: A retrospective, single-centre study. Arthr Res Ther. 2016;18:168. doi: 10.1186/s13075-016-1055-5.
  98. Li Q.Y., Yu F, Zhou F.D., Zhao M.H. Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: A case series study. Med. (Baltimore) 2016;95:e3595. doi: 10.1097/MD. 0000000000003595.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2020